Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombolytic Therapy | 6 | 2025 | 261 | 1.530 |
Why?
|
| Pulmonary Embolism | 4 | 2022 | 234 | 1.180 |
Why?
|
| Cardiac Tamponade | 2 | 2018 | 19 | 1.100 |
Why?
|
| Thrombosis | 6 | 2021 | 318 | 0.760 |
Why?
|
| Haemophilus influenzae | 2 | 2018 | 15 | 0.710 |
Why?
|
| Haemophilus Infections | 1 | 2018 | 8 | 0.540 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 21 | 0.540 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 48 | 0.520 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 226 | 0.520 |
Why?
|
| Renal Veins | 1 | 2017 | 28 | 0.500 |
Why?
|
| Catheterization, Central Venous | 1 | 2018 | 114 | 0.500 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 32 | 0.490 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 140 | 0.490 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 92 | 0.460 |
Why?
|
| Catheterization | 1 | 2017 | 219 | 0.450 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2022 | 180 | 0.450 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 391 | 0.410 |
Why?
|
| Anticoagulants | 3 | 2021 | 484 | 0.390 |
Why?
|
| Recycling | 1 | 2012 | 3 | 0.370 |
Why?
|
| Water Purification | 1 | 2012 | 4 | 0.370 |
Why?
|
| Waste Disposal, Fluid | 1 | 2012 | 4 | 0.370 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 147 | 0.370 |
Why?
|
| Filtration | 1 | 2012 | 26 | 0.370 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 293 | 0.370 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 291 | 0.360 |
Why?
|
| Venous Thrombosis | 3 | 2025 | 264 | 0.360 |
Why?
|
| Ultrasonic Therapy | 2 | 2025 | 44 | 0.360 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 244 | 0.360 |
Why?
|
| Tissue Engineering | 1 | 2013 | 204 | 0.350 |
Why?
|
| Water Pollutants, Chemical | 1 | 2012 | 156 | 0.330 |
Why?
|
| Heparin | 2 | 2021 | 182 | 0.320 |
Why?
|
| Cardiac Catheterization | 5 | 2016 | 307 | 0.300 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2021 | 54 | 0.300 |
Why?
|
| Shock, Cardiogenic | 4 | 2016 | 184 | 0.290 |
Why?
|
| Heart-Assist Devices | 5 | 2016 | 917 | 0.280 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1288 | 0.250 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2013 | 133 | 0.250 |
Why?
|
| Biomarkers | 4 | 2021 | 2020 | 0.240 |
Why?
|
| Exercise Therapy | 1 | 2007 | 96 | 0.240 |
Why?
|
| Nitric Oxide | 1 | 2007 | 286 | 0.230 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 440 | 0.230 |
Why?
|
| Femoral Vein | 1 | 2025 | 42 | 0.220 |
Why?
|
| Polyvinyls | 1 | 2024 | 32 | 0.210 |
Why?
|
| Drug-Eluting Stents | 1 | 2024 | 33 | 0.210 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2024 | 54 | 0.210 |
Why?
|
| Stem Cells | 1 | 2007 | 397 | 0.210 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 232 | 0.200 |
Why?
|
| Humans | 29 | 2024 | 98223 | 0.200 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2024 | 84 | 0.190 |
Why?
|
| Aortic Valve | 2 | 2017 | 258 | 0.190 |
Why?
|
| Phantoms, Imaging | 3 | 2021 | 493 | 0.190 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 339 | 0.180 |
Why?
|
| Fibrinolysis | 1 | 2022 | 35 | 0.170 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2016 | 266 | 0.170 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 53 | 0.170 |
Why?
|
| Embolectomy | 1 | 2020 | 6 | 0.160 |
Why?
|
| Middle Aged | 17 | 2024 | 29494 | 0.160 |
Why?
|
| Antithrombins | 1 | 2020 | 20 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2024 | 9750 | 0.160 |
Why?
|
| Female | 17 | 2024 | 51685 | 0.150 |
Why?
|
| Aged | 13 | 2024 | 21824 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 109 | 0.150 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 52 | 0.150 |
Why?
|
| Europe | 1 | 2020 | 356 | 0.150 |
Why?
|
| Elastic Modulus | 1 | 2019 | 36 | 0.150 |
Why?
|
| Gels | 1 | 2019 | 53 | 0.150 |
Why?
|
| Lithotripsy | 1 | 2019 | 42 | 0.150 |
Why?
|
| Cardiology | 1 | 2020 | 125 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2020 | 240 | 0.140 |
Why?
|
| Microbubbles | 1 | 2019 | 44 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2021 | 720 | 0.140 |
Why?
|
| Recurrence | 2 | 2020 | 1261 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2020 | 675 | 0.140 |
Why?
|
| Acute Disease | 1 | 2020 | 860 | 0.140 |
Why?
|
| Pericardiocentesis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Pericarditis | 1 | 2018 | 14 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 219 | 0.130 |
Why?
|
| Hospital Costs | 1 | 2019 | 118 | 0.130 |
Why?
|
| Binge Drinking | 1 | 2018 | 19 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 177 | 0.130 |
Why?
|
| Male | 17 | 2024 | 47195 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2018 | 295 | 0.130 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 109 | 0.130 |
Why?
|
| Phlebography | 1 | 2017 | 74 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2015 | 81 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2020 | 2598 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 686 | 0.120 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 79 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1784 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 34 | 0.120 |
Why?
|
| Disease Progression | 1 | 2020 | 1612 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 257 | 0.110 |
Why?
|
| Macrophages | 1 | 2019 | 643 | 0.110 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 155 | 0.110 |
Why?
|
| Heart Failure | 3 | 2016 | 1501 | 0.110 |
Why?
|
| Stroke | 1 | 2024 | 1167 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 231 | 0.100 |
Why?
|
| Pericytes | 1 | 2013 | 14 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2016 | 269 | 0.100 |
Why?
|
| Adult | 8 | 2022 | 29548 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 256 | 0.090 |
Why?
|
| Calcium Carbonate | 1 | 2012 | 4 | 0.090 |
Why?
|
| Water Movements | 1 | 2012 | 9 | 0.090 |
Why?
|
| London | 1 | 2012 | 15 | 0.090 |
Why?
|
| Water Pollution | 1 | 2012 | 9 | 0.090 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2013 | 66 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 643 | 0.090 |
Why?
|
| Software | 1 | 2017 | 693 | 0.090 |
Why?
|
| Cell Communication | 1 | 2013 | 223 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 400 | 0.090 |
Why?
|
| Metals, Heavy | 1 | 2012 | 17 | 0.090 |
Why?
|
| RNA Interference | 1 | 2013 | 388 | 0.090 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 131 | 0.090 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 29 | 0.090 |
Why?
|
| Water Supply | 1 | 2012 | 65 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2673 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2016 | 315 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2013 | 502 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 880 | 0.090 |
Why?
|
| Models, Chemical | 1 | 2012 | 186 | 0.090 |
Why?
|
| Catheters | 2 | 2022 | 109 | 0.090 |
Why?
|
| Swine | 2 | 2025 | 592 | 0.080 |
Why?
|
| Cell Movement | 1 | 2013 | 816 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 669 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2021 | 297 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2022 | 945 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 540 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2013 | 746 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2021 | 523 | 0.070 |
Why?
|
| Septal Occluder Device | 3 | 2013 | 52 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1566 | 0.070 |
Why?
|
| Nitrites | 1 | 2007 | 34 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 37 | 0.060 |
Why?
|
| Phenotype | 1 | 2013 | 2653 | 0.060 |
Why?
|
| Exercise Test | 1 | 2007 | 158 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 11031 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 250 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 1528 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 114 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 245 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 721 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 889 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2025 | 36 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2004 | 52 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2025 | 139 | 0.050 |
Why?
|
| Critical Illness | 2 | 2021 | 361 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 158 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 525 | 0.050 |
Why?
|
| Animals | 4 | 2025 | 28950 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 4041 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2022 | 994 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 221 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 227 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2024 | 281 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 406 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3627 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2013 | 75 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 331 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2024 | 817 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2019 | 484 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 7409 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 33 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 138 | 0.040 |
Why?
|
| Prosthesis Design | 2 | 2013 | 309 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2022 | 153 | 0.040 |
Why?
|
| Peptides | 1 | 2004 | 670 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2022 | 198 | 0.040 |
Why?
|
| Mice | 2 | 2013 | 12718 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2022 | 242 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 300 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 244 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 726 | 0.040 |
Why?
|
| Acoustics | 1 | 2019 | 49 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 426 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 168 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 430 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1275 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2575 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 793 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1751 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 119 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 55 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 275 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 5573 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 875 | 0.030 |
Why?
|
| Heart Atria | 1 | 2016 | 255 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 503 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2015 | 100 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 1127 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 50 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1944 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 123 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1303 | 0.020 |
Why?
|
| United States | 2 | 2016 | 8252 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2789 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 992 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 730 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 2001 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1519 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 2012 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2004 | 10 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2004 | 39 | 0.010 |
Why?
|
| Filgrastim | 1 | 2004 | 56 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 49 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 82 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 162 | 0.010 |
Why?
|
| Risk Factors | 2 | 2005 | 6269 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 332 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2856 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1647 | 0.010 |
Why?
|